Researchers at MUSC Hollings Cancer Center have identified a promising new weapon in the fight against head and neck cancers. The preclinical drug attacks cancer cells from within by damaging their mitochondria, the cells’ energy factories.
Researchers at MUSC Hollings Cancer Center have identified a promising new weapon in the fight against head and neck cancers. The preclinical drug attacks cancer cells from within by damaging their mitochondria, the cells’ energy factories.